

Alessandro Capone Curriculum Vitae - Outline



Title: Medical doctor
Address: Via dei giornalisti 15 - 00135 Rome, Italy
Mobile phone: +39 347 51.58.247
E-mail: ale.capone61@gmail.com
UCL: <https://egon.stats.ucl.ac.uk/research/statistics-health-economics/people/honorary-external/alessandro-capone/>
ResearchGate: https://www.researchgate.net/profile/Alessandro_Capone3
LinkedIn: <https://www.linkedin.com/in/alessandro-capone-05b545134>

Education

Background	Year	Venue	Country
Medicine	1992	University of Rome La Sapienza	Italy
Outcomes Research and Epidemiology	1998	University of Rome La Sapienza	Italy
Health and Social Care Management	1999	Bocconi University Milan	Italy
Statistical Methods and Modelling for Economic Evaluations	1999	University of York	UK
Quantitative and Qualitative Analyses Applied to Healthcare	2005 2006	University of Henley	UK

Professional History

Company or Institution	Period	Title	Country	Direct reports
University College London	March 2018	External Research Member	UK	--
Organon	Dec 2020 - Nov 2023	Value Access & Pricing Director	Italy	4
Kingston University London	May 2011 - Jul 2017	Visiting Research Fellow	UK	--
Baxalta-Shire	Oct 2015 - Dec 2016	Value Demonstration and Access Head	Italy	12
C4VI healthcare (Consulting agency)	Jan 2013 - Jun 2015	Principal partner	Italy, UK, Spain	3
MSD	Feb 2012 - Dec 2012	Head of HTA & OR dept.	Italy	2
C4VI healthcare	Oct 2009 - Jan 2012	Principal partner	Italy, UK, Spain, France	5
Henley Centre for Value Improvement (University of Reading)	Jul 2008 - Apr 2011	Visiting Research Fellow	UK	--
Sanofi Pasteur MSD	Oct 2006 - Sep 2009	Health Economics & Market Access Director	Italy	6
C4VI healthcare	Jan 2006 - Sep 2006	Co-founder	Italy, UK	3
Clicon (Consulting agency)	Jan 2002 - Dec 2005	Consultant (OR, HEs)	Italy	5
Merck Sharp & Dohme	May 1999 - Dec 2001	OR Manager	Italy	1
Merck Sharp & Dohme	Jun 1988 - Apr 1999	Several assignments	Italy	--

Professional Performance Indicators

Indicator	Number	Research field
Publications	41 13 h-index	Cardiovascular, health policy, vaccination, NSAIDs, health economics methodology, oncology, virology, immunology.
P&R dossiers	30	Cardiovascular, ophthalmology, vaccines, NSAIDs, neurology, TNF-blockers, COPD, oncology, virology, rare diseases (immunology, haematology), gastroenterology.
New products reimbursed	28	Cardiovascular, ophthalmology, vaccines, NSAIDs, respiratory diseases, oncology, virology, rare diseases (immunology, haematology, oncology).
HTA dossiers	7	Vaccination, neurology, virology, TNF-blockers, cardiovascular.

Collaboration with other university centres and public health bodies

Institution	Department	Period	Country
Regional Health Authority	Local Health Authority (Emilia-Romagna)	Jan. 2003 - Dec. 2004	Italy
Italian Medicines Agency (AIFA)	Drug Consumption Monitoring Centre	Occasionally (starting from 2008)	Italy
University of Rome «Tor Vergata»	Economic Evaluation and HTA (CEIS - EEHTA)	Apr. 2013	Italy

Core Professional Information

1. Proven track record of achievements in terms of pricing and reimbursement for 28 pharmaceutical and biotech products, created and demonstrated the economic and clinical value associated with health interventions (25 drugs), contributed to define strategic and tactical programmes to accelerate the accomplishment of commercial intents. Significantly international experience gained over time (9 yrs) through performing access procedures and generating valuable data in several European countries such as the UK, France, Spain and Greece.
2. Research activity is primarily based on the development and implementation of analytical methods to assess the value, sustainability and effectiveness of new health interventions and public health governance.
 - a. More than 6 years were spent working on large databases belonging to public health bodies (i.e. Local Health Authorities) and containing electronic health records. Pharmacoutilization profiling and adherence to treatment both in chronic (such as hypertension, heart failure and hypercholesterolemia) and in degenerative pathologic conditions (osteoarthritis) were in-depth evaluated and a large body of evidence was generated (18 full papers).
 - b. The epidemiological relevance and costs generated by slow virus-induced diseases such as HPV and HCV were extensively investigated, several evidences produced and many papers published (11 full papers).
 - c. An algorithm which allows a standardized elicitation of utility through the application of the Time-Trade-Off procedure was developed.
 - d. Assessing the potential utilization of large healthcare databases, the use of Artificial Intelligence (AI) was considered. Actually, an innovative assessment of the healthcare governance can be performed utilizing the AI. AI-based analyses can be adopted to tackle healthcare spending growth and improve the effectiveness of health governance systems in ways that also lead to better quality of care. An overview concerning health data interconnection and the analysis of these data using the self-learning AI was published in 2016.
3. During the last few years of consulting activity, a solid expertise on Advanced Therapy Medicinal Products (ATMPs) was built up. In particular, the process of creating and demonstrating the value associated with the engineering of cells or tissues (so-called TEPs) leading to the development of personalised medicine interventions has been implemented.
4. Established and strengthened a large network focused on direct relationship with policy-makers, top government officials, senior executives of health care bodies, scientific societies, third party organizations and other relevant public health decision makers in Italy and in other European countries. Moreover, institutional relationships with the major representatives of government in Italy are constantly being updated.

Professional Experience in Pharma e Biotech corporations - Details

Organon

Value Access and Pricing Director

The Director is responsible for creating and installing controls to ensure alignment with company policy related to contracting activities and other relevant account management activities pertaining to the creation of value associated with company's products. Special attention is focused on internal and external requirements, as well as driving business ownership of stewardship and proper management of the value access and pricing team.

Base: Rome, December 2020 - November 2023

Baxalta - Shire

Head of Value Demonstration and Access

The main responsibility was to evaluate trends in the local environment and develop proper strategies to assure the access of innovative biotechnologies to patients. Moreover, create high-level standards and procedures of partnership with several stakeholders involved in the public health decision making process. Two drugs for rare diseases such as primitive immunodeficiency and acquired haemophilia A (HyQvia and Obizur, respectively) were priced and reimbursed. The pricing and reimbursement dossier of an oncology product (Oncaspar) was prepared and submitted to the health authority.

Base: Rome, October 2015 - December 2016

MSD

Head of HTA and Outcomes Research

Collected, consolidated and elaborated economic, epidemiological, social and outcomes data to create value and support the reimbursement process of new MSD's drug. Designed and ensured the completion of economic evaluations useful in supporting products already in line. Contributed to the activities and objectives accomplishment of HQs, providing an effective cooperation and technical guidance to HQs in adapting global economic models in accordance with local requirements. The pricing and reimbursement procedure concerning boceprevir (Victrelis) has been successfully completed on August 2012.

Base: Rome, February 2012 - December 2012

C4VI healthcare

Partner

The Center for Value Improvement (C4VI) in healthcare is a consulting agency which is dedicated to creating value in healthcare. The C4VI invests his own intellectual capital developing econometric models entirely based on outcome data to support management decisions. The consulting activity is basically focused on pricing and reimbursement of new health technologies, HTA dossiers, HE evaluations and patient access to new and already in-line drugs as well as other health technologies. The activity took place in European countries such as Italy, the UK, France and Spain.

Base: Rome, October 2009 - January 2012;

January 2013 - June 2015;

January 2017 - February 2018

Sanofi Pasteur MSD

Health Economics and Market Access Director

Aligned, optimized, and supported strategic decisions, harmonizing them with the evolving conditions of healthcare business and economic environment (needs, requirements, and procedures of government bodies and health agencies), to deliver more effective care solutions. This ensured that the company could be seen as true partner alongside the other stakeholders including government bodies, physicians, other professional bodies, and patient associations (third sector). Designed, coordinated, and contributed to perform economic evaluations, outcome researches, and health technology assessments which were focused on providing key advice and support to decision-making processes of

public health institutions on HPV vaccination in Italy and in other EU countries. Two vaccines were priced and reimbursed: Gardasil and Rotateq.

Base: Rome, October 2006 - September 2009

C4VI healthcare

Co-founder

The Centre for Value Improvement in healthcare harmonizes different intellectual, human and technical assets to create value in healthcare. C4VI healthcare produces econometric models to increase the value of management decision and competitiveness of pharma and biotech companies and public healthcare providers, supporting the achievement of long-lasting success. Operations started in the UK and Italy and were then expanded to Spain, France and Greece as well.

Base: Rome, January 2006 - September 2006

CliCon - Health Economics and Outcomes Research

Consultant

The Clinical Consulting (CliCon) agency evaluates the clinical and economic impact induced by the introduction of new health technologies (i.e. OR and HE evaluations) and creates value-based dossiers (including probabilistic and budget impact models) to support an valuable process of pricing and reimbursement of drugs.

Base: Rome, January 2002 - December 2005

Merck Sharp & Dohme

Outcomes Research Manager

Developed specific OR programmes to provide the value for money associated with drugs. Provided top management with data of excellence to support the pricing and reimbursement procedures of new drugs: Vioxx (COX-2 inhibitor) and Singulair (leukotriene receptor antagonist). Moreover, co-operated with the USA headquarters to drive the implementation of OR programmes in the south Europe.

Base: Headquarters (Rome), May 1999 - December 2001

Product Manager (Marketing Department - Cardiovascular Division)

Increased the share of Merck's new antihypertensive family compounds (losartan, plain & combo) in the domestic market. Co-operated with European colleagues to develop and roll out strategic marketing plans and core promotional messages for international operations. Two antihypertensive products launched (Cozaar and Hyzaar).

Base: Headquarters, December 1995 - April 1999

Product Manager (Ophthalmic Division)

Managed four in-line products and launched a new drug (Noroxin eye drops).

Base: Headquarters, November 1993 - November 1994

Clinical Monitor, Medical Trainer, and Sales & Marketing Trainer (Medical Department)

Base: Headquarters, May 1990 - October 1993

Sales Representative (Sales Department)

Base: Trento, June 1988 - April 1990

Academic Activities

University College London

External Collaborator - Statistics for Health Economic Evaluation

The most relevant research interest is in the development and implementation of analytic methods to assess the value, sustainability and effectiveness of new health interventions. In particular, methods of utility elicitation, epidemiological and economic relevance associated with slow virus-induced diseases and analysis of databases containing electronic health records.

Base: London, March 2018

Kingston University London

Visiting Research Fellow

The research interests of the Institute for Leadership and Management in Health are focused on the Governance of Public Health as well as measurement, design and analytical methods for Outcomes Research, HTA and health economics in the public health care setting and life science industry.

Base: London, May 2011 - July 2017

Henley Centre for Value Improvement

Visiting Research Fellow

The Henley Centre for Value Improvement is a research centre of the Henley Business School (University of Reading). The main purpose is to help organizations improve their performance by managing cross-functional processes for superior and sustained value creation. Specific support was provided for outcomes research studies and quantitative analysis applied to the pharmaceutical and healthcare sector (i.e. HTA).

Site: Henley-on-Thames, UK; July 2008 - April 2011

Other Academic Assignments

Member of the faculty of the Master in Epidemiology and Biostatistics at the Catholic University of the Sacred Heart in Rome in 2012.

Compliance and persistence with antihypertensive agents: results of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. Invited speaker at the Master in Pharmacoeconomics at the University of Rome "La Sapienza". Rome, October and November 2000.

Academic and Executive Education

Basic knowledge

Medicine and Surgery

University of Rome "La Sapienza" School of Medicine (1992).

Post-graduate education

Health Economics, Outcomes Research, Epidemiology, HTA

Executive and Continuing Professional Education (Outcomes Research). University of Rome La Sapienza, Italy (1998).

Advanced Studies (Epidemiology). University of Rome La Sapienza, Italy (1998).

Advanced Studies (Health and Social Care Management). Bocconi University, Milan, Italy (1999).

Summer School and Advanced Courses (Statistical Methods and Modelling for Economic Evaluation). University of York, UK (1999).

Quantitative and Qualitative Analyses applied to the pharma sector and public healthcare providers. Henley Centre for Value Improvement - University of Henley, UK (2005-06).

Advanced Courses and Pre-work Experiences

Biochemistry Institute

Basic research

Clinical Chemistry - Advanced stage and university assignments. University of Rome "La Sapienza" (1984-86)

National Institute of Health

Research fellowship - Department of Cellular Biology

Immunological Division - Rome (1987)

Specific Work-related Courses

Global Business & Marketing Strategy

Four different stages

Several international locations (1994-96) - Merck Sharp & Dohme

Intensive Business Language Training

Business Language Consultants - London (1993) - Merck Sharp & Dohme

Intitutional Co-operations

Italian Senate Committee on Health

HTA consultant

Supported the president of Senate Committee on Health about resource allocation proposals and procedures pertaining to the EU funds so-called as Recovery Fund (i.e. PNRR).

Site: Rome, July 2020

Economic Evaluation and HTA (CEIS-EEHTA) - IGF Department, Faculty of Economics, University of Rome «Tor Vergata»

Research coordinator

The aim of this research group is to develop advanced methodologies for an economic assessment of health interventions and facilitate the circulation of scientific knowledge between researchers and public health decision makers.

Site: Rome, April 2013

HTAi - Health Technology Assessment International Society

The International society is focused on the promotion of HTA which plays an essential role in modern health care by supporting evidence-based decision making in health care policy and practice. The HTAi's mission is to support the growth of the HTA principles by providing a global forum for the exchange of information, methods, and expertise.

SiHTA - Italian Society of Health Technology Assessment

Among its objectives, the Italian Society of Health Technology Assessment (founded in 2007 as a multi-disciplinary scientific society) supports the mission the Health Technology Assessment International Scientific Society (HTAi). The Society is open to different professionals (economists, clinicians, statisticians, policy makers, but also decision makers such as member of government) who are interested in the scientific and cultural development of HTA in the Italian health system as a model of excellence in healthcare governance.

AIFA - Italian Medicines Agency

Several research activities and cooperations have been accomplished. Among them, one project was specifically focused on the access of new oncology products in Italy (P. Russo et al., Annals of Oncology 2010).

Languages

Italian mother tongue and fluent in English.

The use of personal data is authorized

Publications

1. Capone. Relevant topic left out by the author. JAMA network, August 22, 2020. Comment related to the article: What Happens When COVID-19 Collides With Flu Season? JAMA 2020; 324(10): 923-925. doi:10.1001/jama.2020.15260
2. Capone. Simultaneous circulation of COVID-19 and flu in Italy: potential combined effects on the risk of death? International Journal of Infectious Diseases 2020; 99: 393-396
3. Capone. Really surprising outcomes? JAMA network, April 3, 2020. Comment related to the article: Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020; 323(18): 1775-1776. doi:10.1001/jama.2020.4683
4. Capone A. Towards an effective assessment of the sustainability of health interventions. Igiene e sanità pubblica 2019; 75: 189-199
5. Viti R, Marcellusi A, Capone A, Matucci A, Pignata C, Spadaro G, Vacca A, Marasco C, Agostini C, Mennini FS. Direct and indirect costs of immunoglobulin replacement therapy in patients with common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA) in Italy. Clin Drug Investig 2018 Sep 6. doi: 10.1007/s40261-018-0688-3
6. Capone, A. Cicchetti, FS. Mennini, A. Marcellusi, G. Baio, G. Favato. Health Data Entanglement and artificial intelligence-based analysis: a brand new methodology to improve the effectiveness of healthcare services. Clin Ter 2016; 167: 102-111
7. Haeussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, Bononi M, Costa S, Scambia G, Zweifel P, Capone A, Baio G. Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic Bayesian methodology: The BEST II study. Value in Health 2015; 18(8): 956-968
8. Marcellusi, R. Viti, A. Capone, F.S. Mennini. The economic burden of HCV-induced diseases in Italy. A probabilistic Cost of Illness model. European Review for Medical and Pharmacological Sciences 2015; 19: 1610-1620
9. Marcellusi, A. Capone, G. Favato, F.S. Mennini, G. Baio, K. Haeussler, M. Bononi on behalf of the HPV Italian Collaborative Study Group. Health utilities lost and risk factors associated with HPV-induced diseases in men and women: the HPV Italian Collaborative Study Group. Clinical Therapeutics 2015; 37(1): 156-167
10. Marcellusi, R. Viti, A. Capone, F.S. Mennini. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness. Pharmacoeconomics - Italian Research Articles 2014; 16: 23. <https://doi.org/10.1007/s40276-014-0023-9>
11. G. Favato, G. Baio, A. Capone, A. Marcellusi, FS. Mennini. A novel method to value real options in health care: the case of a multicohort human papillomavirus (HPV) vaccination strategy. Clinical Therapeutics 2013; 35(7): 904-914
12. G. Favato, G. Baio, A. Capone, A. Marcellusi, S. Costa, G. Garganese, M. Picardo, M. Drummond, B. Jonsson, G. Scambia, P Zweifel, FS. Mennini. Transparency or proper study valuation procedures missed? Medical Care 2013; 51(4): 374-378

13. G. Baio, A. Capone, A. Marcellusi, F.S. Mennini, G. Favato. Economic burden of human papillomavirus-related diseases in Italy. *PLoS ONE* 2012; 7(11): e49699. doi:10.1371/journal.pone.0049699
14. G. Favato, G. Baio, A. Capone, A. Marcellusi, S. Costa, G. Garganese, M. Picardo, M. Drummond, B. Jonsson, G. Scambia, P. Zweifel, FS. Mennini. Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases: The BEST Study. *Medical Care* 2012; 50: 1076-1085
15. A. Capone, G. Favato. Human papillomavirus vaccination is not exclusively a matter of price. *Pharmacoeconomics* 2012; May 30(5): 443-444. doi: 10.2165/11599980-000000000-00000
16. FS. Mennini, G. Baio, G. Montagano, G. Cauzillo, F. Locuratolo, G. Becce, L. Gitto, A. Marcellusi, P. Zweifel, A. Capone, G. Favato. Governance of preventive health intervention and on time verification of its efficiency: the GIOVE Study. *BMJ Open* 2012; Mar 15; 2(2): e000736
17. FS. Mennini, D. Panatto, A. Marcellusi, P. Cristoforoni, R. De Vincenzo, E. Di Capua, G. Ferrandina, M. Petrillo, T. Sasso, C. Ricci, N. Trivellizzi, A. Capone, G. Scambia and R. Gasparini. Time Trade-Off procedure for measuring health utilities loss with Human Papillomavirus-induced diseases: A multicenter, retrospective, observational pilot study in Italy. *Clinical Therapeutics* 2011; 33: 1084-1095
18. FS. Mennini, A. Capone, G. Favato. The use of an "old-fashioned method" to assess the clinical and economic impact of a HPV vaccination program. *Gynecologic Oncology* 2011; 123: 175-176
19. Contributed to: P. Russo, FS Mennini, PD Siviero, G. Rasi. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to Regional healthcare providers. *Annals of Oncology* 2010; doi:10.1093/annonc/mdq097
20. P. Russo, A. Capone, V. Pieri, G. Favato. Can savings induced by off-patent drugs balance the increase of pharmaceutical expense associated with the high ageing rate of the Italian population? *Italian Journal of Public Health* 2009; 6(4): 47-54
21. G. Favato, P. Mariani, CF. Print, A. Capone, M. Pelagatti, V. Pieri, A. Marcobelli, E. Tragni, M.G. Trotta, A. Zucchi, AL. Catapano. Effetto dei fabbisogni terapeutici sesso ed età-correlati sui costi di prescrizione nella medicina generale. *PharmacoEconomics - Italian Research Articles* 2008; 10 (2): 89-98
22. G. Favato, P. Mariani, CF. Print, A. Capone, M. Pelagatti, V. Pieri, A. Marcobelli, E. Tragni, MG. Trotta, A. Zucchi and AL Catapano. Effect of age and sex related therapeutic needs on general practices' prescribing cost. The ASSET (Age/Sex Standardised Estimates of Treatment) research model. March 2008. Full text available for download at the Social Science Research Network (SSRN) web page: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1099891
23. G. Favato, P. Mariani, CF. Print, A. Capone, M. Pelagatti, V. Pieri, A. Marcobelli, E. Tragni, MG. Trotta, A. Zucchi and AL Catapano. Knowledge-based governance can improve the elderly population's equity of access to public pharmaceutical funding. The ASSET (Age/Sex Standardised Estimates of Treatment) research model. March 2008. Full text available for download at the Social Science Research Network (SSRN) web page: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1099913
24. G. Favato, P. Mariani, RW Mills, A. Capone, M. Pelagatti. Is age the key determinant of prescribing demand? Results from the ASSET (Age/Sex Standardised Estimates of Treatment) study. *BMJ* 2008; 336

25. Favato G, Mariani P, Mills RW, Capone A, Pelagatti M, Pieri V, Marcobelli A, Trotta MG, Zucchi A, Catapano AL. ASSET (Age/Sex Standardised Estimates of Treatment): A Research Model to Improve the Governance of Prescribing Funds in Italy. *PLoS ONE* 2007; 2(7), e592: 1-8
26. G. Favato, P. Mariani, RW. Mills, A. Capone, M. Pelagatti, V. Pieri, A. Marcobelli, MG. Trotta, A. Zucchi, AL. Catapano. Impact of ageing on prescribing demand. Henley discussion paper series 2007. Full text available for download at the web page: http://publicationslist.org/data/g.favato/ref-50/160207_070207_Impact_of_ageing_on_prescribing_demand_HCVI_discpaper_Final.pdf
27. L. Degli Esposti, M. Di Martino, S. Saragoni, A. Capone, P. Russo, and E. Degli Esposti. Cost offset of lipid-lowering drugs for primary and secondary prevention of cardiovascular disease. *Expert Rev Pharmacoeconomics Outcomes Res* 2005; 5(2): 193-205
28. P. Russo, A. Capone, A. Paolillo. Valutazione dei costi associati alla sclerosi multipla recidivante-remittente in Italia dopo l'introduzione di nuovi farmaci in grado di modificare il decorso della malattia. *Pharmacoeconomics-Italian Research Articles* 2005; 7 (1): 83
29. P. Russo, A. Capone, A. Sturani, and E. Degli Esposti. Frequency of cardiovascular events in patients treated with antihypertensive agents: a cohort study based on claims data generated by primary care practice. *Curr Ther Res* 2004; 65: 398-412
30. L. Degli Esposti, M. Di Martino, S. Saragoni, G. Valpiani, A. Capone, E. Corvi, E. Degli Esposti. Pharmacoutilization of statin therapy after acute myocardial infarction. A real practice analysis based on administrative data. *Ital Heart J* 2004; 5: 120-126
31. L. Degli Esposti, M. Di Martino, S. Saragoni, A. Sgreccia, A. Capone, S. Buda, E. Degli Esposti. Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. *J Clin Hypertens* 2004; 6: 76-82
32. P. Russo, A. Capone, A. Paolillo, F. Macchia, F. Ranzato, G. Costantino, L. Degli Esposti, L. Caprino. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. *Clin Drug Invest* 2004; 24: 409-420
33. Russo P, Capone A, Attanasio E, Baio G, Di Martino M, Degli Esposti L, Marchetta F, Buda S, Degli Esposti E, Caprino L. Pharmacoutilization and costs of osteoarthritis: changes induced by the introduction of a cyclooxygenase-2 inhibitor in clinical practice. *Rheumatology* 2003; 42: 879-887
34. Degli Esposti E, Liverani S, Capone A, Russo P. Liver injury associated with Nimesulide: is it a truly negligible event? *BMJ* 2003; 327: 18-22
35. Russo P, Degli Esposti L, Capone A, Degli Esposti E, Caprino L. Farmacoeconomia dei COXIB nella patologia osteoarticolare: revisione della letteratura. *Health economics and therapeutic pathways* 2003; 4(1S): 5-13
36. Di Martino M, Capone A, Russo P, Degli Esposti L, Ceccarelli P, Buda S, Degli Esposti E, Caprino L. La farmacoutilizzazione delle statine nella pratica clinica: risultati di uno studio di popolazione condotto su database amministrativi e di medici di medicina generale. *Health economics and therapeutic pathways* 2003; 4(1S): 15-23
37. Degli Esposti L, Capone A, Di Martino M, Saragoni S, Berlini S, Russo P, Degli Esposti E. Farmacoepidemiologia e farmacoeconomia della terapia antiipertensiva: uno studio

osservazionale della ASL di Ravenna. *Health economics and therapeutic pathways* 2003; 4(1S): 25-34

38. Baio G, Degli Esposti L, Degli Esposti E, Saragoni S, Capone A, Russo P, Pammolli F. Bayesian cost-effectiveness analysis based on the persistence with antihypertensive treatment. *Expert Rev Pharmacoeconomics Outcomes Res.* 2003; 3(3): 227-236
39. Degli Esposti L, Degli Esposti E, Valpiani, Di Martino M, Saragoni S, Buda S, Baio G, Capone A, Sturani A. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. *Clinical Therapeutics* 2002; 24 (8): 1347-1357
40. Russo P, Capone A, Baio G, Di Martino M, Degli Esposti L, Buda S, Degli Esposti E, Caprino L. Modello valutativo dell'effetto sulla co-prescrizione di gastroprotettori osservato durante il trattamento dell'artrosi con rofecoxib. *Reumatismo* 2002; 54: 331-339
41. Degli Esposti L, Capone A, Degli Esposti E, Valpiani G, Di Martino M, Baio G, Russo P, Buda S, Sturani A, Caprino L. Analisi della persistenza e delle risorse allocate nel trattamento farmacologico dell'ipertensione arteriosa. *Health economics and therapeutic pathways* 2002; 3: 161-170

Posters, Presentations and Talks

1. Capone A, Mennini FS, Cicchetti A, Marcellusi A, Baio G, Torlone R, Favato G. Health Data Entanglement and artificial intelligence-based analyses to improve the effectiveness of services and tackle the healthcare spending growth. ISPOR 20th Annual International Meeting. May 16-20 2015, Philadelphia, USA. *Value in Health* 2015; 18(3): A103
2. Haeussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, Bononi M, Scambia G, Capone A, Baio G. The Effect of Herd Immunity in Different Human Papillomavirus Vaccination Strategies: An Economic Evaluation of the Best II Study. ISPOR 17th Annual European Congress. November 8-12 2014, Amsterdam, The Netherlands. *Value in Health* 2014; 17(7): A674
3. Marcellusi A, Viti R, Capone A, Mennini FS. Direct and Indirect Cost of HCV-Related Diseases in Italy: An Incidence-Based Probabilistic Approach. ISPOR 17th Annual European Congress. November 8-12 2014, Amsterdam, The Netherlands. *Value in Health* 2014; 17(7): A671
4. Haussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, Bononi M, Scambia G, Capone A, Baio G. The effect of herd immunity in human papillomavirus vaccination strategies: an economic evaluation of the BEST II study. ISPOR 19th Annual International Meeting. May 31-June 4 2014, Montreal, Canada. *Value in Health* 2014; 17(3): A85
5. De Vincenzo R, Marcellusi A, Capone A, Conte C, Favato G, Mennini FS, Baio G, Haeussler K, Giuliani M, Picardo M, Cristoforoni P, Scambia G. Utility loss with HPV-induced diseases in men and women. EUROGIN 2013, International Multidisciplinary Congress. November 3-6 2013, Florence, Italy
6. Marcellusi A, Capone A, Haeussler K, Baio G, Mennini FS, Favato G. Risk Factors Influencing the Viral Transmission and the Potential Development of HPV-Induced Pathologies. ISPOR 16th Annual European Congress. November 2-6 2013, Dublin, Ireland. *Value in Health* 16 (7): A343
7. FS Mennini, A Marcellusi, G Baio, K Haeussler, G Favato, A Capone. Loss of health utilities due to HPV-induced diseases in men and women: a multicenter Italian study. ISPOR 18th Annual International Meeting. May 18-22 2013, New Orleans, USA. *Value in Health* 2013; 16(3): A38
8. Favato G, Baio G, Capone A, Marcellusi A, Mennini FS. Il Burden of Disease indotto dalle patologie HPV-correlate in Italia. XII Conferenza Nazionale di Sanità Pubblica (SITI). Comunicazione Orale. La Sanità pubblica tra globalizzazione, nuove esigenze di salute e sostenibilità economica: la sfida dell'integrazione. Roma 12-15 Ottobre 2011. Libro degli Atti, pag. 521, abstract 624
9. F.S. Mennini, G. Baio, A. Capone, A. Marcellusi, G. Favato, S. Costa, G. Garganese, M. Picardo, M. Drummond, B. Jonsson, G. Scambia, P. Zweifel. The BEST Study: Bayesian modelling assessing the Effectiveness of a vaccination Strategy To prevent hpv-related diseases. Oral presentation at the 8th World Congress on Health Economics. International Health Economics Association (iHEA); July 10-13 2011, Toronto, Canada
10. Mennini FS, Baio G, Capone A, Marcellusi A, Favato G, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P. Bayesian modelling assessing the effectiveness of a vaccination strategy to prevent HPV-related diseases: The BEST Study. ISPOR 16th Annual International Meeting. May 21-25 2011, Baltimore, USA. *Value in Health* 2011; volume 14, Issue 3, Page A165

11. G. Favato, M. Nurullah, A. Capone, V. Pieri. Expanded access to free prescription drugs and its impact on social welfare: the case of cholesterol-lowering agents in Italy. Subjective Probability, Utility, and Decision Making Biennial Conference; 21 - 26 Aug 2011, Kingston upon Thames, UK
12. FS. Mennini, D. Panatto, P. Cristoforoni, E. Di Capua, R. De Vincenzo, G. Ferrandina, M. Petrillo, T. Sasso, C. Ricci, G. Scambia, N. Trivellizzi, A. Capone, A. Marcellusi, R. Gasparini. The TTO approach to measure patients' preferences for health states associated with HPV-related pathologies. Presented at the 7th Annual Meeting of the Health Technology Assessment International Society. Dublin, Ireland, 6th - 9th June 2010
13. Mennini FS, Giorgi Rossi P, Palazzo F, Cohet C, LARGERON N, and Capone A. Cost-effectiveness analysis of the implementation of a quadrivalent (6, 11, 16, 18 types) human papillomavirus vaccine to the existing Italian cervical cancer screening programme. Presented at the 24th International Papillomavirus Conference and Clinical Workshop (IPCCW). Beijing, China, November 3-9, 2007. Abstracts book; pag. 192, M5-53
14. Russo P, Capone A, Degli Esposti L, Buda S, Di Martino M, Ceccarelli P, Degli Esposti E. Pharmacoutilization of statins in primary care: preliminary results of a cross-sectional analysis on a large population database. 31° Congresso Nazionale della Società Italiana di Farmacologia, Trieste 26-29 giugno 2003. Abstract 122
15. Russo P, Capone A, Degli Esposti L, Sturani A, Buda S, Di Martino M, Saragoni S, Degli Esposti E. Cardiovascular events and persistence with statins in primary and secondary prevention: a population-based analysis including 19.178 patients treated between 1996 and 2000. Oral presentation at the European Society of Cardiology. August 30 - September 3, Vienna, Austria. European Heart Journal 2003; 24 (supplement August/September): A706
16. Russo P, Degli Esposti L, Capone A, Di Martino M, Ceccarelli P, Buda S, Degli Esposti E, Caprino L. Appropriateness of the use of statins in clinical practice: results of a study of population conducted on administrative database and general practitioners. Oral communication at the 64° Congresso Nazionale della Società Italiana di Cardiologia. Roma, 6-10 December 2003. Italian Heart Journal 2003; vol. 4 (suppl 6): abstract C179
17. L. Degli Esposti, M. Di Martino, E. Degli Esposti, S. Buda, S. Saragoni, S. Liverani A. Capone. The impact of information management on persistence with antihypertensive drug therapy. American Society of Hypertension, 18th Annual Scientific Meeting. May 14-17, 2003, New York, USA. American Journal of Hypertension 2003; 16(5): Pag. 233A, P-540
18. G. Baio, L. Degli Esposti, S. Saragoni, E. Degli Esposti, A. Capone, F. Pammolli. PCV28 Persistence with antihypertensive drug treatment: an evaluation based on a bayesian cost-effectiveness approach. ISPOR 5th Annual European Congress. November 2-5 2002, Rotterdam, The Netherlands. Value in Health 2002; 5(6): p488